MAGEA3: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
 
m (Bot: HTTP→HTTPS)
Line 1: Line 1:
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{Infobox_gene}}
{{PBB_Controls
'''Melanoma-associated antigen 3''' (MAGE-A3) is a [[protein]] that in humans is encoded by the ''MAGEA3'' [[gene]].<ref name="pmid1840703">{{cite journal |vauthors=van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T | title = A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma | journal = Science | volume = 254 | issue = 5038 | pages = 1643–7 |date=Jan 1992 | pmid = 1840703 | pmc =  | doi =10.1126/science.1840703  }}</ref><ref name="pmid8575766">{{cite journal |vauthors=Rogner UC, Wilke K, Steck E, Korn B, Poustka A | title = The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28 | journal = Genomics | volume = 29 | issue = 3 | pages = 725–31 |date=Mar 1996 | pmid = 8575766 | pmc = | doi = 10.1006/geno.1995.9945 }}</ref><ref name="entrez"/>
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = yes
| update_citations = yes
}}


<!-- The GNF_Protein_box is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
== Genetics ==
{{GNF_Protein_box
| image =
| image_source =
| PDB =  
| Name = Melanoma antigen family A, 3
| HGNCid = 6801
| Symbol = MAGEA3
| AltSymbols =; HIP8; HYPD; MAGE3; MAGEA6; MGC14613; MAGE-3b; MAGE3B; MAGE6; MGC52297
| OMIM = 300174
| ECnumber = 
| Homologene = 55892
| MGIid = 
| GeneAtlas_image1 = PBB_GE_MAGEA3_209942_x_at_tn.png
| GeneAtlas_image2 = PBB_GE_MAGEA3_214612_x_at_tn.png
| Function = {{GNF_GO|id=GO:0003674 |text = molecular_function}}
| Component = {{GNF_GO|id=GO:0005575 |text = cellular_component}}
| Process = {{GNF_GO|id=GO:0008150 |text = biological_process}}
| Orthologs = {{GNF_Ortholog_box
    | Hs_EntrezGene = 4102
    | Hs_Ensembl = ENSG00000197172
    | Hs_RefseqProtein = NP_005353
    | Hs_RefseqmRNA = NM_005362
    | Hs_GenLoc_db = 
    | Hs_GenLoc_chr = X
    | Hs_GenLoc_start = 151685308
    | Hs_GenLoc_end = 151688896
    | Hs_Uniprot = P43357
    | Mm_EntrezGene = 
    | Mm_Ensembl = 
    | Mm_RefseqmRNA = 
    | Mm_RefseqProtein = 
    | Mm_GenLoc_db = 
    | Mm_GenLoc_chr = 
    | Mm_GenLoc_start = 
    | Mm_GenLoc_end = 
    | Mm_Uniprot = 
  }}
}}
'''Melanoma antigen family A, 3''', also known as '''MAGEA3''', is a human [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: MAGEA3 melanoma antigen family A, 3| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4102| accessdate = }}</ref>


<!-- The PBB_Summary template is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
This gene is a member of the [[melanoma-associated antigen]] gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location [[Xq28]]. They have been implicated in some hereditary disorders, such as [[dyskeratosis congenita]].<ref name="entrez">{{cite web | title = Entrez Gene: MAGEA3 melanoma antigen family A, 3| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4102| accessdate = }}</ref>
{{PBB_Summary
 
| section_title =
== Function and Clinical relevance ==
| summary_text = This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita.<ref name="entrez">{{cite web | title = Entrez Gene: MAGEA3 melanoma antigen family A, 3| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4102| accessdate = }}</ref>
 
}}
The normal function of MAGE-A3 in healthy cells is unknown.<ref name="pmid22156658">{{cite journal |vauthors=Decoster L, Wauters I, Vansteenkiste JF | title = Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. | journal = Annals of Oncology | volume = 23 | issue =  | pages = 1387–1393 |date=Dec 2011 | pmid = 22156658 | pmc = | doi = 10.1093/annonc/mdr564 }}</ref> The presence of the antigen on tumor cells has been associated with worse prognosis. In one study, high levels of MAGE-A3 in [[lung adenocarcinoma]] were associated with shorter survival.<ref name="pmid16299236">{{cite journal |author1=Ali O. Gure |author2=Ramon Chua |author3=Barbara Williamson |author4=Mithat Gonen |author5=Cathy A. Ferrera |author6=Sacha Gnjatic |author7=Gerd Ritter |author8=Andrew J.G. Simpson |author9=Yao-T. Chen |author10=Lloyd J. Old |author11=Nasser K. Altorki | title = Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer | journal = Clinical Cancer Research | volume = 11 | issue = 22 | pages = 8055–8062 |date=Nov 2005 | pmid = 16299236 | pmc = | doi =  10.1158/1078-0432.CCR-05-1203 }}</ref>
 
MAGE-A3 is a tumor-specific protein, and has been identified on many tumors including [[melanoma]], [[non-small cell lung cancer]], [[hematologic malignancies]], among others.<ref>{{cite web|author=Corporate Comms |url=http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10076.htm |title=New data on MAGE-A3 cancer immunotherapy support potential novel options of treating non-small cell lung cancer and melanoma |publisher=Us.gsk.com |date= |accessdate=2012-10-16}}</ref> Currently, [[GlaxoSmithKline]] is developing a [[cancer vaccine]] targeting MAGE-A3.  The vaccine is a fusion protein of MAGE-A3 and ''[[Haemophilus influenzae]]'' [[protein D]], combined with a proprietary immunoadjuvant.<ref>{{cite web|url=http://www.google.com/patents/US20100008980 |title=Patent US20100008980 - Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with ... - Google Patents |publisher=Google.com |date=2008-01-08 |accessdate=2012-10-16}}</ref>
 
== References ==
{{reflist}}


==References==
{{reflist|2}}
==Further reading==
==Further reading==
{{refbegin | 2}}
{{refbegin | 2}}
{{PBB_Further_reading
*{{cite journal   |vauthors=Brasseur F, Rimoldi D, Liénard D, etal |title=Expression of MAGE genes in primary and metastatic cutaneous melanoma. |journal=Int. J. Cancer |volume=63 |issue= 3 |pages= 375–80 |year= 1995 |pmid= 7591235 |doi=10.1002/ijc.2910630313 }}
| citations =
*{{cite journal   |vauthors=Kocher T, Schultz-Thater E, Gudat F, etal |title=Identification and intracellular location of MAGE-3 gene product. |journal=Cancer Res. |volume=55 |issue= 11 |pages= 2236–9 |year= 1995 |pmid= 7757970 |doi=  }}
*{{cite journal | author=van der Bruggen P, Traversari C, Chomez P, ''et al.'' |title=A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. |journal=Science |volume=254 |issue= 5038 |pages= 1643-7 |year= 1992 |pmid= 1840703 |doi=  }}
*{{cite journal   |vauthors=De Plaen E, Arden K, Traversari C, etal |title=Structure, chromosomal localization, and expression of 12 genes of the MAGE family. |journal=Immunogenetics |volume=40 |issue= 5 |pages= 360–9 |year= 1994 |pmid= 7927540 |doi=10.1007/BF01246677 }}
*{{cite journal | author=Brasseur F, Rimoldi D, Liénard D, ''et al.'' |title=Expression of MAGE genes in primary and metastatic cutaneous melanoma. |journal=Int. J. Cancer |volume=63 |issue= 3 |pages= 375-80 |year= 1995 |pmid= 7591235 |doi=  }}
*{{cite journal  |vauthors=Ding M, Beck RJ, Keller CJ, Fenton RG |title=Cloning and analysis of MAGE-1-related genes. |journal=Biochem. Biophys. Res. Commun. |volume=202 |issue= 1 |pages= 549–55 |year= 1994 |pmid= 8037761 |doi= 10.1006/bbrc.1994.1963 }}
*{{cite journal | author=Kocher T, Schultz-Thater E, Gudat F, ''et al.'' |title=Identification and intracellular location of MAGE-3 gene product. |journal=Cancer Res. |volume=55 |issue= 11 |pages= 2236-9 |year= 1995 |pmid= 7757970 |doi=  }}
*{{cite journal   |vauthors=Gaugler B, Van den Eynde B, van der Bruggen P, etal |title=Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes |journal=J. Exp. Med. |volume=179 |issue= 3 |pages= 921–30 |year= 1994 |pmid= 8113684 |doi=10.1084/jem.179.3.921  | pmc=2191409  }}
*{{cite journal  | author=De Plaen E, Arden K, Traversari C, ''et al.'' |title=Structure, chromosomal localization, and expression of 12 genes of the MAGE family. |journal=Immunogenetics |volume=40 |issue= 5 |pages= 360-9 |year= 1994 |pmid= 7927540 |doi= }}
*{{cite journal  |vauthors=Maruyama K, Sugano S |title=Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides |journal=Gene |volume=138 |issue= 1–2 |pages= 171–4 |year= 1994 |pmid= 8125298 |doi=10.1016/0378-1119(94)90802-8 }}
*{{cite journal | author=Ding M, Beck RJ, Keller CJ, Fenton RG |title=Cloning and analysis of MAGE-1-related genes. |journal=Biochem. Biophys. Res. Commun. |volume=202 |issue= 1 |pages= 549-55 |year= 1994 |pmid= 8037761 |doi= 10.1006/bbrc.1994.1963 }}
*{{cite journal   |vauthors=Valmori D, Liénard D, Waanders G, etal |title=Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients |journal=Cancer Res. |volume=57 |issue= 4 |pages= 735–41 |year= 1997 |pmid= 9044853 |doi=  }}
*{{cite journal  | author=Gaugler B, Van den Eynde B, van der Bruggen P, ''et al.'' |title=Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. |journal=J. Exp. Med. |volume=179 |issue= 3 |pages= 921-30 |year= 1994 |pmid= 8113684 |doi=  }}
*{{cite journal   |vauthors=Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, etal |title=Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library |journal=Gene |volume=200 |issue= 1–2 |pages= 149–56 |year= 1997 |pmid= 9373149 |doi=10.1016/S0378-1119(97)00411-3  }}
*{{cite journal | author=Maruyama K, Sugano S |title=Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides. |journal=Gene |volume=138 |issue= 1-2 |pages= 171-4 |year= 1994 |pmid= 8125298 |doi=  }}
*{{cite journal   |vauthors=Mallon AM, Platzer M, Bate R, etal |title=Comparative Genome Sequence Analysis of the Bpa/Str Region in Mouse and Man |journal=Genome Res. |volume=10 |issue= 6 |pages= 758–75 |year= 2000 |pmid= 10854409 |doi=10.1101/gr.10.6.758  | pmc=310879  }}
*{{cite journal | author=Rogner UC, Wilke K, Steck E, ''et al.'' |title=The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. |journal=Genomics |volume=29 |issue= 3 |pages= 725-31 |year= 1996 |pmid= 8575766 |doi= 10.1006/geno.1995.9945 }}
*{{cite journal   |vauthors=Jang SJ, Soria JC, Wang L, etal |title=Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis |journal=Cancer Res. |volume=61 |issue= 21 |pages= 7959–63 |year= 2001 |pmid= 11691819 |doi=  }}
*{{cite journal | author=Valmori D, Liénard D, Waanders G, ''et al.'' |title=Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. |journal=Cancer Res. |volume=57 |issue= 4 |pages= 735-41 |year= 1997 |pmid= 9044853 |doi= }}
*{{cite journal   |vauthors=Consogno G, Manici S, Facchinetti V, etal |title=Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 |journal=Blood |volume=101 |issue= 3 |pages= 1038–44 |year= 2003 |pmid= 12393675 |doi= 10.1182/blood-2002-03-0933 }}
*{{cite journal | author=Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, ''et al.'' |title=Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. |journal=Gene |volume=200 |issue= 1-2 |pages= 149-56 |year= 1997 |pmid= 9373149 |doi=  }}
*{{cite journal   |vauthors=Strausberg RL, Feingold EA, Grouse LH, etal |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899–903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899  | pmc=139241 }}
*{{cite journal | author=Mallon AM, Platzer M, Bate R, ''et al.'' |title=Comparative genome sequence analysis of the Bpa/Str region in mouse and Man. |journal=Genome Res. |volume=10 |issue= 6 |pages= 758-75 |year= 2000 |pmid= 10854409 |doi= }}
*{{cite journal   |vauthors=Guo J, Wen DR, Huang RR, etal |title=Detection of multiple melanoma-associated markers in melanoma cell lines by RT in situ PCR |journal=Exp. Mol. Pathol. |volume=74 |issue= 2 |pages= 140–7 |year= 2003 |pmid= 12710945 |doi=10.1016/S0014-4800(03)00012-1  }}
*{{cite journal | author=Jang SJ, Soria JC, Wang L, ''et al.'' |title=Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. |journal=Cancer Res. |volume=61 |issue= 21 |pages= 7959-63 |year= 2001 |pmid= 11691819 |doi= }}
*{{cite journal   |vauthors=Zerbini A, Pilli M, Soliani P, etal |title=Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma |journal=J. Hepatol. |volume=40 |issue= 1 |pages= 102–9 |year= 2004 |pmid= 14672620 |doi=10.1016/S0168-8278(03)00484-7  }}
*{{cite journal | author=Consogno G, Manici S, Facchinetti V, ''et al.'' |title=Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. |journal=Blood |volume=101 |issue= 3 |pages= 1038-44 |year= 2003 |pmid= 12393675 |doi= 10.1182/blood-2002-03-0933 }}
*{{cite journal   |vauthors=Gerhard DS, Wagner L, Feingold EA, etal |title=The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC) |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504 | pmc=528928 }}
*{{cite journal | author=Strausberg RL, Feingold EA, Grouse LH, ''et al.'' |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899-903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899 }}
*{{cite journal   |vauthors=Zhou M, Peng JR, Zhang HG, etal |title=Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry |journal=Immunol. Lett. |volume=99 |issue= 1 |pages= 113–21 |year= 2005 |pmid= 15885805 |doi= 10.1016/j.imlet.2005.02.007 }}
*{{cite journal | author=Guo J, Wen DR, Huang RR, ''et al.'' |title=Detection of multiple melanoma-associated markers in melanoma cell lines by RT in situ PCR. |journal=Exp. Mol. Pathol. |volume=74 |issue= 2 |pages= 140-7 |year= 2003 |pmid= 12710945 |doi=  }}
*{{cite journal   |vauthors=Hudolin T, Juretic A, Spagnoli GC, etal |title=Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue |journal=Prostate |volume=66 |issue= 1 |pages= 13–8 |year= 2006 |pmid= 16114059 |doi= 10.1002/pros.20312 }}
*{{cite journal  | author=Zerbini A, Pilli M, Soliani P, ''et al.'' |title=Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. |journal=J. Hepatol. |volume=40 |issue= 1 |pages= 102-9 |year= 2004 |pmid= 14672620 |doi=  }}
*{{cite journal   |vauthors=Miyagawa N, Kono K, Mimura K, etal |title=A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells |journal=Oncology |volume=70 |issue= 1 |pages= 54–62 |year= 2006 |pmid= 16446550 |doi= 10.1159/000091185 }}
*{{cite journal  | author=Gerhard DS, Wagner L, Feingold EA, ''et al.'' |title=The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121-7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504 }}
*{{cite journal | author=Zhou M, Peng JR, Zhang HG, ''et al.'' |title=Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry. |journal=Immunol. Lett. |volume=99 |issue= 1 |pages= 113-21 |year= 2005 |pmid= 15885805 |doi= 10.1016/j.imlet.2005.02.007 }}
*{{cite journal | author=Hudolin T, Juretic A, Spagnoli GC, ''et al.'' |title=Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. |journal=Prostate |volume=66 |issue= 1 |pages= 13-8 |year= 2006 |pmid= 16114059 |doi= 10.1002/pros.20312 }}
*{{cite journal | author=Miyagawa N, Kono K, Mimura K, ''et al.'' |title=A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. |journal=Oncology |volume=70 |issue= 1 |pages= 54-62 |year= 2006 |pmid= 16446550 |doi= 10.1159/000091185 }}
}}
{{refend}}
{{refend}}


{{protein-stub}}
 
{{WikiDoc Sources}}
{{gene-X-stub}}

Revision as of 06:01, 4 September 2017

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Melanoma-associated antigen 3 (MAGE-A3) is a protein that in humans is encoded by the MAGEA3 gene.[1][2][3]

Genetics

This gene is a member of the melanoma-associated antigen gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita.[3]

Function and Clinical relevance

The normal function of MAGE-A3 in healthy cells is unknown.[4] The presence of the antigen on tumor cells has been associated with worse prognosis. In one study, high levels of MAGE-A3 in lung adenocarcinoma were associated with shorter survival.[5]

MAGE-A3 is a tumor-specific protein, and has been identified on many tumors including melanoma, non-small cell lung cancer, hematologic malignancies, among others.[6] Currently, GlaxoSmithKline is developing a cancer vaccine targeting MAGE-A3. The vaccine is a fusion protein of MAGE-A3 and Haemophilus influenzae protein D, combined with a proprietary immunoadjuvant.[7]

References

  1. ↑ van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (Jan 1992). "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma". Science. 254 (5038): 1643–7. doi:10.1126/science.1840703. PMID 1840703.
  2. ↑ Rogner UC, Wilke K, Steck E, Korn B, Poustka A (Mar 1996). "The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28". Genomics. 29 (3): 725–31. doi:10.1006/geno.1995.9945. PMID 8575766.
  3. ↑ 3.0 3.1 "Entrez Gene: MAGEA3 melanoma antigen family A, 3".
  4. ↑ Decoster L, Wauters I, Vansteenkiste JF (Dec 2011). "Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development". Annals of Oncology. 23: 1387–1393. doi:10.1093/annonc/mdr564. PMID 22156658.
  5. ↑ Ali O. Gure; Ramon Chua; Barbara Williamson; Mithat Gonen; Cathy A. Ferrera; Sacha Gnjatic; Gerd Ritter; Andrew J.G. Simpson; Yao-T. Chen; Lloyd J. Old; Nasser K. Altorki (Nov 2005). "Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer". Clinical Cancer Research. 11 (22): 8055–8062. doi:10.1158/1078-0432.CCR-05-1203. PMID 16299236.
  6. ↑ Corporate Comms. "New data on MAGE-A3 cancer immunotherapy support potential novel options of treating non-small cell lung cancer and melanoma". Us.gsk.com. Retrieved 2012-10-16.
  7. ↑ "Patent US20100008980 - Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with ... - Google Patents". Google.com. 2008-01-08. Retrieved 2012-10-16.

Further reading


Retrieved from "https://www.wikidoc.org/index.php?title=MAGEA3&oldid=1423019"